1 556

Cited 17 times in

Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study

Authors
 Kim, Do Young  ;  Park, Beom Jin  ;  Kim, Yun Hwan  ;  Han, Kwang-Hyub  ;  Cho, Sung Bum  ;  Cho, Kyu Ran  ;  Uhm, Sun-Ho  ;  Choe, Jae-Gol  ;  Choi, Jong Young  ;  Chun, Ho Jong  ;  Lee, Han Chu  ;  Gwon, Dong Il  ;  Lee, Kwang Hun MD††  ;  Yoon, Jung-Hwan  ;  Chung, Jin Wook  ;  Kim, Chang Won  ;  Heo, Jeong  ;  Kim, Jae Kyu  ;  Joo, Young Eun 
Citation
 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, Vol.38(5) : 495-501, 2015 
Journal Title
 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 
ISSN
 0277-3732 
Issue Date
2015
MeSH
Adult ; Aged ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/therapy* ; Chemoembolization, Therapeutic/adverse effects ; Chemoembolization, Therapeutic/methods* ; Female ; Humans ; Liver Neoplasms/mortality ; Liver Neoplasms/therapy* ; Male ; Microspheres ; Middle Aged ; Prospective Studies ; Republic of Korea ; Survival Rate ; Treatment Outcome ; Yttrium Radioisotopes/therapeutic use*
Keywords
hepatocellular carcinoma ; radioembolization ; Yttrium-90
Abstract
OBJECTIVES: The aim of this prospective study was to reveal the efficacy and safety of Yttrium-90 (Y) radioembolization in Korean patients with hepatocellular carcinoma (HCC). METHODS: A total of 40 HCC patients were prospectively recruited from 7 centers. The response to treatment was assessed on the basis of the modified Response Evaluation Criteria in Solid Tumors criteria. The time to progression and overall survival were also evaluated, and the assessment of safety was done according to National Cancer Institute Common Terminology Criteria, Version 3.0. RESULTS: Forty-two treatments of Y radioembolization were carried out. Median follow-up was 29 months. At 3 months, the complete response, partial response (PR), and stable disease were seen in 4 (10.0%), 19 (47.5%), and 15 (37.5%) patients, respectively. The response rate was 57.5% (23/40), and disease control rate was 95% (38/40) at 3 months. The response rate at 6 months was 63.9% (23/36), and disease control rate was 83.3% (30/36). The median time to progression was 18 months. During follow-up, 10 HCC-related deaths occurred and the 3-year survival rate was 75%. In 19 patients with Barcelona Clinic Liver Cancer-B stage, the 3-year survival rate was 50%. The tumor number (>5) was the only significant predictor associated with survival. The most common adverse event was abdominal pain of mild to moderate degree, and all the complications were manageable. Twenty-six (65%) patients underwent other treatments such as transarterial chemoembolization because of local progression or remnant viable lesion.
Full Text
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00000421-201510000-00010&LSLINK=80&D=ovft
DOI
10.1097/COC.0b013e3182a78dba
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Lee, Kwang Hun(이광훈)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/141252
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links